
Precision Psychedelic Therapy

Bioshares24 - 12 July 2024

ASX : TYP

This presentation has been authorised for release by the Board of Tryptamine Therapeutics Limited





DISCLAIMERS

The information contained in this presentation") has been prepared by Tryp Therapeutics Inc. ("Tryp" or the "Company") and contains information pertaining to the business, operations and assets of the Company. The information contained in this Presentation (a) is provided as at the date hereof and is subject to change without notice, (b) is for informational purposes only and does not purport to contain all information (including all material information) that may be necessary or desirable to fully and accurately evaluate the Company, (c) did not take into account the investment objectives, financial situation and particular investor, (d) is not to be considered as a recommendation by the Company that any person make an investment in Tryp, and (e) further advice should be obtained from a professional investment adviser before taking any action on any information without advice do so entirely at their own risk.

This Presentation does not constitute an offer to sell or solicitation of an offer to buy any of the securities of Tryp. The sole purpose of this Presentation, in paper or electronic form, is strictly for information purposes. Neither Tryp, nor any of its current or proposed directors, officers, owners, managers, partners, consultants, employees, affiliates or representations, or for the accuracy, completeness, fairness, or susfiliates or assume any legal liability or responsibility for any action taken in reliance upon this Presentation.

Forward Looking Information. This Presentation contains forward looking statements with respect to Tryp. By their nature, forward looking statements involve risks and uncertainties and are subject to a variety of factors that could cause actual results to differ materially from the results suggested by the forward-looking statements. In addition, the forward-looking statements require Tryp to make assumptions and are subject to inherent risks and uncertainties. There is significant risk that the forward-looking statements will not prove to be accurate, that Tryp's assumptions may not be correct and that actual results are distingted by the use of terminology such as "anticipate", "may", "continue", "could", "estimate", "forecast", "plan", "potential" and similar expressions. Forward looking statements contained in this Presentation may include, but are not limited to statements with respect the outlook for the psilocybin industry; the completion and timing of clinical studies; the ability of any patents resulting from Tryp's patent applications to protect the commercial prospects of its assets; the achievement, and the timing of clinical studies; demographic and market size/trends; forecasts of revenue and financial projections/growth potential; Tryp's ability to obtain market size/trends; forecasts of revenue and financial projections/growth potential; Tryp's ability to obtain certain approvals, the accuracy of cost estimates, ability to obtain sufficient capital on satisfactory terms, availability of equipment and supplies, changes in customer demand, the successful and timely implementation of capital projects, currency exchange rates and the impact of changes in applicable laws and regulations. The forward-looking statements that accuracy of cost estimates, ability to obtain certain approvals, the accuracy of cost estimates, ability to obtain certain approvals, the accuracy of cost estimates, ability to obtain certain approvals, the accuracy of cost estimates, ability to obtain certain approvals, the accura

Third-Party Information. This Presentation includes market and industry data obtained from various publicly available sources and other sources believed by the Company to be reliable. Although the Company believes it to be reliable, the Company has not independently verified any of the data from thirdparty sources referred to in this Presentation or analyzed or verified the underlying reports relied upon or referred to by such sources, or ascertained the underlying assumptions relied upon by such sources. The Company does not make any representation or warranty, express or implied as to the accuracy of such information. No responsibility or liability is accepted for that information or those opinions or for any errors, omissions, misstatements (negligent or otherwise) or for any communication written or otherwise, contained or referred to in this Presentation. Some numbers in this Presentation may not be

Accordingly, neither the Company nor any of its directors, officers, employees, advisers, associated persons or subsidiaries are liable for any direct, indirect or consequential loss or damage suffered by any person as a result of relying upon any statement in this Presentation or any document supplied with this Presentation, or by any future communications in connection with those documents and all of those losses and damages are expressly disclaimed.

Electronic Form. This Presentation may have been sent to you in an electronic form. You are reminded that documents transmitted via this medium may be altered or changed during the process of electronic transmission. You are responsibility to take precautions to ensure that it is free from viruses and other items of a destructive nature. As a consequence of the above, neither the Company nor any director, officer, employee or agent of any of them or any affiliate of any such preson accepts any liability whatsoever in respect of on difference between the document diritheted to you in electronic format and the hard copy version the hard roopy version.

This Presentation and its contents are confidential and should not be distributed, published or reproduced in whole or in part or disclosed by recipients to any other person without the prior written consent of the Company. The Company does not assume responsibility for liabilities, losses or damages suffered by the recipients of this Presentation or any other person as a result of the circulation, reproduction or use of this Presentation.

Psilocybin. Psilocybin is currently a Schedule III drug under the Controlled Drugs and Substances Act, S.C. 1996, c. 19 (the "CDSA") and it is a criminal offence to possess substances under the CDSA without a prescription. Health Canada has not approved psilocybin as a drug. While the Company is focused on developing products using psilocybin, the Company does not have any direct or indirect involvement with the illegal selling, production or distribution of any substances. The Company does not currently manufacture, store or otherwise handle psilocybin directly and will only do so through agents within laboratory and clinical trial settings conducted within approved regulatory frameworks. The Company's products that contain psilocybin or other psychedelic compounds will not be commercialized prior to applicable regulatory approval, which will only be granted if clinical evidence of safety and efficacy for the intended uses is successfully developed.

All medicines carry risks and specialist prescribers, such as registered psychiatrists are best placed to assess the suitability of a new medication against a patient's individual circumstances and medical history before proceeding.

Adverse effects of psilocybin and its derivatives can include temporary increase in blood pressure and a raised heart rate. There may be some risk of psychosis in predisposed individuals. These effects of psilocybin and its derivatives are unlikely at low doses and in the treatment regimens used in psychedelicassisted psychotherapy and appropriately managed in a controlled environment with direct medical supervision.

Corporate Presentation - July 2024

02

TRYPTAMINE

A Precision Approach to Psychedelic Medicine

With a focus on solving: EATING DISORDERS & CHRONIC PAIN

Tryp is a clinical stage drug development company developing an innovative and scalable IV-infused psilocin solution which can be used in conjunction with psychotherapy to address unmet medical needs

Infusion refers to the continuous administration of the drug via the intravenous route and provides a clinician with control over the administration of the solution



Corporate Presentation – July 2024

Investment Highlights

Pioneering a precision approach to psychedelics, targeting precise drug blood levels in patients

Transformative and commercially scalable intellectual property (IV-Infused Psilocin)

- Addresses the critical limitations of oral dosing of psilocybin
- Platform has broad applicability and out-licensing potential
- Multiple near term value creating catalysts

Positioned to take advantage of recent positive changes to TGA regulations in Australia

First mover advantage and IP protection for indications targeted

Multiple clinical trials ongoing:

- Positive Phase 2 efficacy data announced for Binge Eating Disorder (80% reduction in episodes) with oral psilocybin (TRP8802) at University of Florida
- Patient Dosing completed in Phase 2 clinical trial with University of Michigan in Fibromyalgia
- UofM researchers to present efficacy data at the International Association for the Study of Pain Conference from 5 9 August in the Netherlands
- Massachusetts General Hospital (Harvard University) have enrolled patients for Phase 2 IBS study with first dosing expected in July
- First cohort (3 participants) has been dosed with IV-psilocin through 140 minute IV-infusion (CMAX, Adelaide) : Second cohort (mid-dose) to begin during July
- Preparation for first "active patient" clinical study in Australia for IV-infused psilocin (BED) underway

Experienced management team with proven biotech and drug approval success

World-class scientific advisory board chaired by renowned expert, Robin Carhart-Harris





TRYPTAMINE



Corporate overview

Snapshot:	
ASX code:	ТҮР
Shares on issue:	1.089Bn
Market capitalisation: (at \$0.02 per share)	\$22.8m
Cash at bank: (as at 29 May 2024)	~\$6.7m
Debt:	Nil

Board of Directors	
Non-Executive Chairman	Mr. Mark Davies
Chief Executive Officer	Mr. Jason Carroll
Chief Business Officer	Mr. Peter Molloy
Non-Executive Director	Mr. Chris Ntoumenopoulos
Non-Executive Director	Mr. Clarke Barlow
Non-Executive Director	Mr. Gage Jull



Major shareholders (at 5 July 2024)	
Dr. William James Garner	16.4%
Citicorp Nominees P/L	5.7%
Haywood Securities	4.1%
Mr. Jason Carroll	3.2%
Computershare Investor Services	2.7%
Mr. Herwig Janssen	2.2%
Mr. Ludwig Criel & Ms. Yasmin Janssen	2.2%
Top 10:	49.7% (+0.5%)
Top 100:	81.0% (+0.9%)

World class team with proven Leadership

TRYPTAMINE



JASON CARROLL Chief Executive Officer

A seasoned and successful leader with over 30 years experience in healthcare sector



JIM GILLIGAN, PH.D. Chief Scientific Officer

Over 35 years experience in Biopharmaceutical industry



JIM O'NEILL Chief Financial Officer

Over 30 years as a finance executive with public and private multi-national businesses



PETER MOLLOY Chief Business Officer

Over 25 years as an entrepreneur, advisor and institutional investor in the healthcare sector



MICHAEL SILVERMAN, M.D. Chief Medical Officer

Over 30 years experience of clinical development in biotech sector

SCIENTIFIC ADVISORY BOARD



ROBIN CARHART-HARRIS PH.D., (CHAIR OF SAB)

Global expert on use of psychedelics for medical indications

UCSE





DANIEL CLAUW, M.D.

World –renowned expert on fibromyalgia and nociplastic pain

MUNIVERSITY OF MICHIGAN



RACHEL WEVRICK, PH.D.

Leading researcher in genetic development, including eating disorders

ALBERTA



JOEL CASTELLANOS, M.D.

Leading chronic pain researcher and physician

UC San Dieg



WILLIAM SCHMIDT, PH.D.

Expert in drug development for Pain indications





DEREK OTT, M.D.

30+ years of experience in the pharmaceutical industry including manufacturing and drug delivery

UCLA

Corporate Presentation – July 2024

Tryp is underpinned by exceptional sector tailwinds

Research into the neuroplastic benefits of psilocybin is 8-fold higher today than any other time in clinical history •

1S

- There are 133 clinical trials underway using psilocybin however almost all of these will not lead to an approvable dossier or expanded clinical use
- Tryp is focused on achieving the five core requirements for success:

 - Selectiveness and time sensitivity
 Outcome focused data generation
 Proprietary protection at ever level
 Pharmaceutical vs psychedelic expertise
 Stable, scalable commercial products

Tryp is confident that its lead program, TRP-8803 is an outlier in the use of psychedelic medicine

Number of publications referring to psilocybin per year (via PubMed)



IV-infused Psilocin: A Precision Approach to Psychedelics

	IV-infused Psilocin	Oral Psilocybin *
Short treatment duration of 1-2 hours	~	~8-10 hours
Quick onset of psychedelic state (~15 minutes)	 	1-2 hours
Precision targeting of drug blood levels in patients		highly variable
Quickly reversible in emergency		\mathbf{x}
Strong IP positioning	 ✓ 	\bigotimes
Commercially scalable	 ✓ 	?
	·i	

* Companies developing oral psilocybin include: Compass Pathways, USONA

Corporate Presentation – July 2024



Pilot Studies Using Oral Psilocybin

De-risking TRP-8803 trials

A cost effective method for identifying safety and efficacy signals for new indications

Access to a common and readily available generic molecule for clinical trials now

Earliest possible enhancement of IP portfolio

Ability to optimise clinical trial protocols

Establishes collaborations with key universities

Reduces clinical risk while allowing for acceleration of proprietary drug development

TRP-8802 - ORAL PSILOCYBIN

Pilot studies to identify positive signal in new indications

Partnered with leading academic institutions

TRP-8803 - IV PSILOCIN

Pathway for Phase 2b trials and beyond

Commercially scalable platform

Corporate Presentation – July 2024



Current

Trial Pipeline



*Healthy volunteer dose ranging study in H1 2024 will support IND submissions for Phase 2a studies in patients

**The timetable is indicative only and is subject to change.

10



TRP-8803: Healthy Human Volunteer Study (Australia) A global first study now underway

IV-Infused Psilocin

- Precision targeting of drug blood levels
- Fast onset time to psychedelic state (approx. 15 minutes)
- Short duration of treatment (1-2 hours)

- Reversible in emergency
- IP protection
- Commercially scalable
- Enables clinical studies in multiple indications

HREC approved trial expected to complete in H2 2024

PRODUCT	NO. OF PATIENTS	COLLABORATOR	DESIGN	DATA READ OUT	NEXT STEPS	
TRP-8803	9	iNGENu, C-Max	Open label with therapist support	H2 2024	First patient treatment (H1 2024)	


IV-infused psilocin: overcomes the limitations of oral psilocybin


Limitations of orally administered psilocybin:

- High patient variability in terms of drug blood levels (refer graphic)
 - Psilocybin is converted into psilocin, the psychoactive metabolite, in the body
 - Percent conversion varies for each patient:
 - Effectiveness of enzymes responsible for conversion is specific to each patient
 - First pass metabolism through liver contributes to variable blood levels of psilocin
 - Dose-escalation to ensure efficacy simply leads to increased side-effects
 - May negatively impact efficacy and safety

• Long duration of treatment of approx. 8-10 hours


- Induction phase into psychedelic state can be 1-2 hours
- Psychedelic state can persist for an additional 6-8 hours
- Therapists needed with patient throughout treatment period
- Poor health economics makes commercial scale-up challenging
- Patient & Physician acceptance
- Intellectual Property





Dosing Variability of Oral Psilocybin

Blood concentrations of psilocin after single dose of 15mg, 25mg & 30mg psilocybin




Clinical Pha

Volume 113, Issue 4 April 2023 Pages 747-751

Clin Pharma and Therapeutics, Volume: 113, Issue: 4, Pages: 822-831, First published: 12 December 2022, DOI: (10.1002/cpt.2821)




15



Corporate Presentation – July 2024 Adapted from : Clin Pharma and Therapeutics, Volume: 113, Issue: 4, Pages: 822-831, First published: 12 December 2022, DOI: (10.1002/cpt.2821)






Corporate Presentation – July 2024 Adapted from : Clin Pharma and Therapeutics, Volume: 113, Issue: 4, Pages: 822-831, First published: 12 December 2022, DOI: (10.1002/cpt.2821)

Clinical Pharmacology & Therapeutics

15



15






Focus on 25 mg psilocybin



15




Corporate Presentation – July 2024 Adapted from : Clin Pharma and Therapeutics, Volume: 113, Issue: 4, Pages: 822-831, First published: 12 December 2022, DOI: (10.1002/cpt.2821)

Focus on 25 mg psilocybin




15



Corporate Presentation – July 2024 Adapted from : Clin Pharma and Therapeutics, Volume: 113, Issue: 4, Pages: 822-831, First published: 12 December 2022, DOI: (10.1002/cpt.2821)






Corporate Presentation – July 2024 Adapted from : Clin Pharma and Therapeutics, Volume: 113, Issue: 4, Pages: 822-831, First published: 12 December 2022, DOI: (10.1002/cpt.2821)

Clinical Pharmacology & Therapeutics

15




15



Corporate Presentation – July 2024 Adapted from : Clin Pharma and Therapeutics, Volume: 113, Issue: 4, Pages: 822-831, First published: 12 December 2022, DOI: (10.1002/cpt.2821)





Adapted from : Clin Pharma and Therapeutics, Volume: 113, Issue: 4, Pages: 822-831, First published: 12 December 2022, DOI: (10.1002/cpt.2821)

15

Binge Eating Disorder: Phase 2a clinical trial

BINGE EATING DISORDER (BED)

Recurring episodes of eating large quantities of food and feeling unable to stop

Approximately 30% of people seeking weight loss treatments show signs of BED

No currently approved treatments developed specifically for BED

TRYPTAMINE

"We are very excited for the potential of TRYP's treatment. The potential impact on patients' lives is that it would be life changing for them."

Jennifer Miller, MD, Professor, University of Florida, Principal Investigator

"These results from a single dose of psilocybin combined with therapy are clinically meaningful and highly promising. The magnitude of changes for most participants in binge eating, anxiety, and depression are dramatic.."


Jessie Dallery, Ph.D. Professor, University of Florida, Lead Psychologist

PRODUCT	NO. OF PATIENTS	COLLABORATOR	DESIGN	DATA READ OUT	NEXT STEPS
TRP-8802	6	UNIVERSITY of FLORIDA	Open label with psychotherapy	Data announced Q1 2023	Scientific paper publication


Positive interim data announced in January 2023, including mean reduction >80% for Binge Eating Score Confirmed as viable target for future studies using TRP-8803

University of Florida Phase 2a Interim Analysis:

Significant reduction in frequency & extent of binge eating (daily, 4 weeks)




Question 2: On how many of these times did you have a sense of having lost control over your eating (at the time that you were eating)?



Corporate Presentation - July 2024


University of Florida Phase 2a Interim Analysis:

Durable effect on binge eating episodes



University of Florida Phase 2a Interim Analysis:

Significant fall in Hospital Anxiety & Depression Scores (HADS)



HADS Anxiety Score

HADS Depression Score



Fibromyalgia: Phase 2a clinical trial

FIBROMYALGIA

- Chronic condition causing widespread pain and fatigue
- Many cases linked to adverse physical or emotional events
- Limited success with currently approved drugs
- Co-morbidities include depression and health-related anxiety, sleep disturbances

"Existing treatment options for fibromyalgia are often ineffective and show significant side effects. We are excited to be working with the team at Tryp Therapeutics, who have shown exceptional scientific rigor in their approach to evaluate a new treatment paradigm for the millions of patients suffering from fibromyalgia and other pain-related indications"

Daniel Clauw, MD, Professor, University of Michigan

PRODUCT	NO. OF PATIENTS	COLLABORATOR	DESIGN	DATA READ OUT	NEXT STEPS
TRP-8802	Up to 10	UNIVERSITY OF MICHIGAN	Open label with psychotherapy	Initial data expected in H2 2024	Trial completion & Await data

First patient dosed in December 2023 Patient Dosing ongoing

Corporate Presentation – July 2024

TRYPTAMINE

Irritable Bowl Syndrome: Phase 2a clinical trial

IBS

Chronic abdominal pain + altered bowel habits

Affects 10-15% worldwide (~790M people)*; leading cause of work absenteeism;**

Associated with fibromyalgia, chronic fatigue, depression, anxiety

More common in those with early life adversity/trauma

Pathophysiology: visceral hypersensitivity

90% of serotonin synthesized in gut; enteric nervous system***

"There is tremendous potential for the treatment of debilitating IBS and other disorders of gut-brain interaction by utilizing the combined administration of psilocybin and psychotherapy. Our clinical study will examine how psilocybin-assisted psychotherapy may alter important brain networks involved in chronic pain and gastrointestinal-specific anxiety in IBS to bolster the neural flexibility in these patients and thereby reduce visceral hypersensitivity"

Erin Mauney, MD, Massachusetts General Hospital

PRODUCT	NO. OF PATIENTS	COLLABORATOR	DESIGN	DATA READ OUT	NEXT STEPS
TRP-8802	Up to 10	MASSACHUSETTS GENERAL HOSPITAL	Open label with psychotherapy	H2 2024	First patient enrolment

IND Letter to Proceed received from FDA, and IRB approval granted Next steps: First patient enrolment

*<u>https://gi.org/topics/irritable-bowel-syndrome</u> ** <u>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5010380/</u> *** https://www.nature.com/articles/s41598-022-05756-0

Corporate Presentation - July 2024

Robust Intellectual Property Portfolio

Patent applications and trade secrets based on novel methods for manufacturing, formulation, dosing, and specific disease indications

- Filed a provisional patent in March 2021 (US 63/161,070) covering TRP-8803 (IV-infused Psilocin); converted to PCT filing March 2022; published September 22, 2022
- Provisional patent application covering the use of psilocybin in the treatment of Binge Eating Disorder (BED) filed June 2022
- Provisional patent application for the treatment of fibromyalgia submitted September 2022
- Provisional patent application for salt & co-formers of TRP-8803 filed September 2022
- Provisional patent for IBS filed January 2, 2028

$\frac{MORRISON}{FOERSTER}$

Allens > < Linklaters

Corporate Presentation – July 2024

Multiple Near-Term Milestones and Catalysts*

Timeframe Catalyst Status Completion of Tryp Therapeutics Inc. acquisition H1 2024 \checkmark \$6.5m capital raise H1 2024 Recommencement of trading on ASX H1 2024 Appointments to strengthen Scientific Advisory Board H1 2024 Start of TRP-8803 Phase 1 trial (Australia) H1 2024 TRP-8802 Fibromyalgia Phase 2a patient enrolment (in collaboration with University of Michigan) H1 2024 TRP-8802 Irritable Bowel Syndrome (IBS) Phase 2a trial commencement (alongside Harvard University) H2 2024 Completion of TRP-8803 Phase 1 trial (Australia) and interim results H2 2024 TRP-8802 Fibromyalgia Phase 2a interim data H1 2025 TRP-8802 IBS Phase 2a interim data H1 2025 TRP-8802 Fibromyalgia Phase 2a final data H1 2025 TRP-8803 Phase 2 trial authorisations H1 2025 TRP-8803 Phase 2 trial eating disorder trial commencement (Australia) H1 2025 TRP-8802 IBS Phase 2a final data H2 2025 Commencement of TRP-8803 Phase 2 chronic pain trial (Australia) H2 2025

*The timetable is indicative only and is subject to change (Calendar year is used)

Corporate Presentation - July 2024



Psychedelic Market Landscape

Company	Ticker	Mkt cap (AUD)	Compound	Stage	Indication(s)
AbbVie Inc.	NYSE: ABBV	414Bn	Multiple	Phase 1 / 2 completed	Multiple
Compass Pathways	NASDAQ: CMPS	\$912m	Psilocybin	Phase 3	Treatment resistant depression, PTSD, Anorexia
GH Research	NASDAQ: CMPS	469.7m	5-MeO-DMT	Phase 1/2 completed	Treatment resistant depression
Atai Life Sciences	NASDAQ: ATAI	458m	Psilocybin	Preclinical - Phase 2	Depression, Anxiety, Schizophrenia, Opioid Use Disorder, PTSD
Cybin	NYSE: CYBN	227.2m	Psilocybin, DMT	Preclinical - Phase 2	Depression, Anxiety, Alcohol Use Disorder, Neuroinflammation
Lykos	NASDAQ: MNMD	154.7m	LSD, MDMA	Phase 2	Anxiety, ADHD
Icannex Healthare	ASX: IHL / NASDAQ: IXHL	\$102.6m	Psilocybin & CBD	Phase 1 completed	Anxiety
Little Green Pharma	ASX: LGP	42m	Psilocybin & CBD	Preclinical	Treatment resistant depression
Emyria	ASX: EMD	24.5m	MDMA & CBD	Preclinical	Parkinson's, Fibrotic Disease, pain
Tryptamine Therapeutics	ASX: TYP	22.8m	Psilocin & psilocybin	Phase 2	Eating disorders, Chronic pain (nociplastic)

Market data at 22 January 2024 *USD/AUD exchange rate of 1.52

Corporate Presentation - July 2024

Investment highlights

A Precision Approach to Psychedelic Medicine

- **IV-Infused Psilocin** overcomes critical challenges of oral psilocybin dosing, providing significant competitive advantages
- Transformative and commercially scalable intellectual property (IV-Infused Psilocin)
- Potential beneficiary of recent positive changes to TGA regulation in Australia
- Multiple near-term value-creating catalysts
- First mover advantage and IP protection for each indication being targeted
- Clinical trials ongoing, with positive efficacy data already announced
- Partnered with multiple leading academic institutions for Phase 2 trials
- 43.5% R&D credit for qualifying clinical trials in Australia
- Experienced management team with proven biotech and drug approval success
- World-class Scientific Advisory Board

27

UTHERAPEUTICS Contact

Jason Carroll Chief Executive Officer jcarroll@tryptherapeutics.com

Henry Jordan Six Degrees Investor Relations henry.jordan@sdir.com.au

Website: www.tryptherapeutics.com

Socials: X (Twitter) @tryptherapeutic

